IP Library Granted Patent US 11,458,473
Granted Patent B2
US 11,458,473 · App. 16/564,268 · Granted Oct 4, 2022

Systems and devices for analysis of samples

Inventors: Vincent Linder (Tewksbury, MA); David Steinmiller (Half Moon Bay, CA); Jason Taylor (Windham, NH)
Assignee: OPKO Diagnostics, LLC
B01L3/502746B01L3/5027B01L3/50273B01L3/502715B01L3/502738G01N21/05G01N21/59G01N21/64G01N21/76G01N33/54313G01N33/54366G01N33/57434B01L7/52B01L2200/025B01L2200/026B01L2200/027B01L2200/028B01L2200/0673B01L2200/0684B01L2200/143B01L2200/146B01L2200/147B01L2300/021B01L2300/023B01L2300/027B01L2300/04B01L2300/0654B01L2300/0816B01L2300/0867B01L2300/12B01L2300/14B01L2300/16B01L2300/168B01L2300/1827B01L2300/1894B01L2400/049B01L2400/0475B01L2400/0666B01L2400/082G01N2201/02G01N2201/062G01N2201/0612G01N2201/0621G01N2201/0697G01N2333/96433Y10T137/0324Y10T436/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,458,473
App. No.
16/564,268
Granted
Oct 4, 2022
Kind
B2
Abstract

Systems and methods for analysis of samples, and in certain embodiments, microfluidic sample analyzers configured to receive a cassette containing a sample therein to perform an analysis of the sample are described. The microfluidic sample analyzers may be used to control fluid flow, mixing, and sample analysis in a variety of microfluidic systems such as microfluidic point-of-care diagnostic platforms. Advantageously, the microfluidic sample analyzers may be, in some embodiments, inexpensive, reduced in size compared to conventional bench top systems, and simple to use. Cassettes that can operate with the sample analyzers are also described.

Claims (24)

1. A device comprising:

a first component comprising a first channel formed in a first material and including at least a first port;

a second component comprising a second channel formed in a second material and including at least a second port, the second channel comprising at least one measurement zone, wherein the measurement zone comprises a binding partner for prostate specific antigen (PSA);

a fluidic connector that can be connected to the first and second components, the fluid connector comprising a fluid path including a fluid path inlet and a fluid path outlet, wherein upon connection, the fluid path inlet fluidically connects to the first port and the fluid path outlet fluidically connects to the second port to allow fluid communication between the first and second channels, and

wherein the first and second channels are not in fluid communication with one another absent connection via the fluidic connector.

2. The device of claim 1 , wherein the first channel includes at least one portion having a cross-sectional dimension greater than 200 microns.

3. The device of claim 1 , wherein the first material has a water vapor permeability of less than about 5.0 g·mm/m 2 ·d.

4. The device of claim 1 , wherein the second channel includes at least one portion having a cross-sectional dimension less than 200 microns.

5. The device of claim 1 , wherein the first material is different from the second material.

6. The device of claim 1 , wherein both the first port and the second port are accessible from a top surface of the first component or the second component.

7. The device of claim 1 , wherein the binding partner for PSA is an anti-PSA antibody.

8. The device of claim 1 , wherein the binding partner for PSA is selected from the group consisting of binding partners that bind free-PSA, complexed-PSA, and pro-PSA.

9. The device of claim 1 , wherein the binding partner for PSA is immobilized on one or more walls of the at least one measurement zone.

10. The device of claim 1 , wherein the binding partner for PSA is configured to bind to PSA in a sample.

11. The device of claim 10 , wherein the sample is whole blood, serum, or plasma.

12. The device of claim 10 , wherein the binding partner for PSA is configured to bind to PSA in the sample in a way that is proportional to the amount of PSA in the sample.

13. The device of claim 10 , wherein the PSA in the sample is selected from the group consisting of free-PSA, complexed-PSA, and pro-PSA.

14. The device of claim 1 , wherein the second channel comprises at least four measurement zones.

15. The device of claim 1 , comprising an optical system configured to measure a signal at the at least one measurement zone.

16. The device of claim 15 , wherein the optical system comprises one or more detectors.

17. The device of claim 16 , wherein the optical system is configured to use optical detection to detect the presence of PSA in a sample at the at least one measurement zone.

18. The device of claim 16 , wherein the optical system is configured to use optical detection to detect the binding and/or non-binding of a detection antibody to a positive and/or negative control.

19. The device of claim 17 , wherein the optical system is configured to measure an optical density to detect the presence of PSA in the sample at the at least one measurement zone.

20. The device of claim 1 , wherein the first material and/or the second material comprises polystyrene, PMMA, or a cyclo-olefin copolymer.

Assignments (3)
MERGER Recorded Jan 7, 2020
From: CLAROS DIAGNOSTICS, INC.
To: CLAROS MERGER SUBSIDIARY, LLC UNDER THE NAME OF CLAROS DIAGNOSTICS, LLC
Reel/Frame 051432/0433 →
CHANGE OF NAME Recorded Jan 7, 2020
From: CLAROS DIAGNOSTICS, LLC
To: OPKO DIAGNOSTICS, LLC
Reel/Frame 051491/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2020
From: LINDER, VINCENT; STEINMILLER, DAVID; TAYLOR, JASON
To: CLAROS DIAGNOSTICS, INC.
Reel/Frame 051401/0360 →
Continuity (7)
Continuation 15588548 · May 5, 2017
Continuation 14554205 · Nov 26, 2014
Division 13088102 · Apr 15, 2011
Provisional Application 61363002 · Jul 9, 2010
Provisional Application 61325023 · Apr 16, 2010
Provisional Application 61325044 · Apr 16, 2010
Related Publication 20200070164A1 · Mar 5, 2020
Cited By (2)
US 1,094,761 US 12,674,785